An observational study in Malaria, Plasmodium Vivax Infection and Plasmodium Falciparum Infection, sponsored by Rafiullah Hotak. Completed at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Rafiullah Hotak · Observational
This study aimed to compare platelet count patterns in patients infected with either Plasmodium vivax or Plasmodium falciparum, the two most common malaria species in Pakistan. Thrombocytopenia (low platelet count) is a common complication of malaria and can help in identifying disease severity. We conducted this research at a tertiary care hospital in Peshawar, Pakistan, from April to September 2023. A total of 171 adult patients with confirmed malaria infections were enrolled. We measured their platelet counts at admission, day 3, and day 7, and analyzed the severity and progression of thrombocytopenia. The study found that while P. vivax was more common, P. falciparum was more likely to cause severe thrombocytopenia. Understanding these differences helps healthcare providers identify high-risk patients earlier and manage malaria more effectively. The study was approved by the institutional review board of Lady Reading Hospital, Peshawar.
1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.
This study's enrollment of 177 is below the median of 600 across 218 observational studies indexed under Malaria.
Browse Malaria studies →This is the only study on the registry with Rafiullah Hotak as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adult patients (aged 18 and above) presenting to a tertiary care hospital in Peshawar, Pakistan, with confirmed malaria infection. Participants were included based on microscopic confirmation of either Plasmodium vivax or Plasmodium falciparum infection and evaluated for platelet trends and clinical outcomes.
Exclusion Criteria:
Adult patients (≥18 years) with microscopically confirmed Plasmodium vivax malaria. Platelet counts and clinical data were collected at admission, day 3, and day 7 to assess the frequency and severity of thrombocytopenia.
Adult patients (≥18 years) with microscopically confirmed Plasmodium falciparum malaria. Platelet counts and clinical data were collected at admission, day 3, and day 7 to assess the frequency and severity of thrombocytopenia.
Proportion of patients with thrombocytopenia
The percentage of patients with platelet counts \<50×10³/µL at admission, compared between the P. vivax and P. falciparum groups.
Time frame: 0 days
Platelet count recovery over time
Change in mean platelet count at admission, day 3, and day 7, for each group.
Time frame: Day 0 to Day 7
Frequency of malaria-related complications
Number of patients developing clinical complications (e.g., acute kidney injury, neurological involvement, anemia, jaundice), stratified by malaria species.
Time frame: Within 7 days of admission
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.